Analysts at Raymond James reiterated their rating on Scotts Miracle-Gro Co SMG, even though the company's fiscal first quarter results were "somewhat" below their expectations. Nevertheless, the analysts saw a number of "encouraging" signs in the earnings report.
The Analyst
Joseph Altobello reiterated his Outperform rating on the Scotts Miracle-Gro and raised the price target from $71 to $80.
The Thesis
Scotts Miracle-Gro posted an adjusted net loss of $1.39 per share, which was 29 percent lower than Raymond James' estimate of $1.15 and below the consensus of $1.25. Altobello pointed out that the miss was mostly due to temporary Cost of Goods Sold and non-operating items such as a lower tax rate and diluted share count.
The company's earnings of $298.1 million grew by 35 percent on the year, slightly lower than the 38 percent the analyst had expected.
Altobello also pointed out that Scotts Miracle-Gro's U.S. consumer segment enjoyed a 9-percent sales growth during the quarter, which was above their estimates of a 1-percent growth.
The cannabis-focused Hawthorne subsidiary grew its sales by 84 percent, versus Raymond James' expectations of 108 percent. Hawthorne sales were boosted by the acquisition of Sunlight Supply, but on a comparable basis the sales fell by less than 10 percent on the year, which is an improvement from the previous quarters' drops of 30-40 percent.
In this way, Altobello said, Scotts Miracle-Gro is showing solid trends for its U.S. consumer segment and the integration of Sunlight is well on track to provide synergies of around $0.60 per share.
Price Action
Scotts Miracle-Gro's stock closed Friday $74.18.
Related Links:
Video: A Lesson On Indoor Cannabis Cultivation With Canndescent's Adrian Sedlin
Organigram's Revenue Jumps 287% Sequentially After Canadian Legalization
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
